Latest Content

Camrelizumab Combo Extends Survival in Metastatic Cervical Cancer

October 20th 2025, 8:41pm

By Kyle Doherty

Article

Camrelizumab plus famitinib extended progression-free survival to 11.1 months versus 7.5 months with chemotherapy in recurrent or metastatic cervical cancer.

Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer

October 20th 2025, 8:15pm

By Silas Inman

Article

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Trodelvy Plus Keytruda Upholds Quality of Life in TNBC

October 20th 2025, 7:29pm

By Kristie L. Kahl

Article

Trodelvy plus Keytruda may maintain quality of life and slow physical decline in metastatic triple-negative breast cancer.

ADC Use Rapidly Growing in Metastatic Breast Cancer Treatment

October 20th 2025, 5:38pm

By Alex Biese

Article

Antibody-drug conjugate treatment rates increased 3.7-fold from 2021 to 2023 for patients with metastatic breast cancer.

Cancer Vaccine Plus Keytruda Slow Advanced Melanoma Progression

October 20th 2025, 5:37pm

By Alex Biese

Article

The cancer vaccine IO102-IO103 plus Keytruda was associated with a clinically relevant improvement in median progression-free survival.

Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer

October 20th 2025, 3:14pm

By Ariana Pelosci

Article

Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer across subgroups.

Facing Mortality After Cancer, and Choosing to Live Fully

October 20th 2025, 1:00pm

By Karen Cohn

Article

After her follicular lymphoma diagnosis, Karen Cohn reflects on how cancer reshaped her view of mortality and her choice to keep living fully.

Ivonescimab Combo Improves Progression-Free Survival in Advanced NSCLC

October 19th 2025, 9:15pm

By Kristi Rosa

Article

Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer

October 19th 2025, 8:44pm

By Gina Mauro

Article

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

Tiragolumab Treatment Combo Misses Mark in Advanced Liver Cancer

October 19th 2025, 8:13pm

By Spencer Feldman

Article

Tiragolumab added to Tecentriq plus Avastin did not improve progression-free survival in untreated advanced hepatocellular carcinoma, phase 3 data show.

Imfinzi Combo Improves Progression Free Survival in Ovarian Cancer

October 19th 2025, 7:50pm

By Kyle Doherty

Article

Platinum chemo with Imfinzi, Avastin, and Lynparza improved progression-free survival versus chemo and Avastin but did not extend overall survival.

Loqtorzi Extends Survival in HER2-Positive Advanced Urothelial Cancer

October 19th 2025, 7:26pm

By Tim Cortese

Article

Loqtorzi improved progression-free and overall survival versus chemotherapy in HER2-expressing advanced urothelial cancer.

Supplemental Xtandi Does Not Improve Metastasis-Free Survival in High-Risk Prostate Cancer

October 19th 2025, 6:57pm

By Ryan Scott

Article

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in high-risk localized prostate cancer.

Imfinzi With Chemo Produces Inconclusive Outcomes in Phase 3 Mesothelioma Study

October 19th 2025, 6:37pm

By Sabrina Serani

Article

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer

October 19th 2025, 6:18pm

By Roman Fabbricatore

Article

Adding Tecentriq to chemo resulted in survival outcomes comparable to placebo plus chemo in patients with advanced or recurrent endometrial cancer.